Commigileadin A: A new triterpenoid from Commiphora gileadensis aerial parts

Hossam M Abdallah; Gamal A Mohamed; Sabrin R M. Ibrahim; Abdulrahman E Koshak; Ibrahim Alnashri; Abdullah Alghamdi; Abdulghani Aljohani; Abdulrahman Khairy

Articles

Abstract

Pharmacognosy Magazine,2022,18,78,256-260.

DOI:10.4103/pm.pm_118_21

Published:July 2022

Type:Original Article

Authors:

Author(s) affiliations:

Hossam M Abdallah¹, Gamal A Mohamed², Sabrin R M. Ibrahim³, Abdulrahman E Koshak², Ibrahim Alnashri², Abdullah Alghamdi², Abdulghani Aljohani², Abdulrahman Khairy²
¹ Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Cairo, Egypt
² Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
³ Department of Chemistry, Preparatory Year Program, Batterjee Medical College, Jeddah, Saudi Arabia; Department of Pharmacognosy, Faculty of Pharmacy, Assiut University, Assiut, Egypt

Abstract:

Background: Genus Commiphora (Burseraceae) includes about 150 species of aromatic shrubs located in Africa, India, and the Arabian region. C. gileadensis L. has been used for treating several ailments such as constipation, urinary retention, headache, jaundice, joint pain, liver and stomach diseases, and inflammatory disorders. Objectives: In this work, a phytochemical investigation of C. gileadensis aerial parts was carried out. Moreover, the antimicrobial potential of the new metabolite was assessed. Materials and Methods: The aerial parts were extracted at room temperature with methanol (MeOH). The MeOH extract was subjected to various chromatographic techniques to separate the bio-constituents. Their structures were exhaustively specified by utilizing diversified spectroscopic data and comparing them with the literature. The antimicrobial potential of the new compound 1 was assessed toward Bacillus cereus, Escherichia coli, Staphylococcus aureus, and Clostridium albicans. Results: A new friedelan triterpenoid, commigileadin A [3,11-dioxo-(D: A)-friedo-olean-27-al] (1) and four known metabolites, namely, Stigmasterol (2), naringenin (3), naringenin-4-methyl ether (4), and kaempferol (5) were obtained. Compound 1 possessed moderate activity toward B. cereus (inhibition zone diameter (IZD): 12.6 mm and minimum inhibitory concentration [MIC]: 8.9 μg/mL) in comparison to ciprofloxacin (IZD: 21.1 mm and MIC: 2.5 μg/mL, respectively). Conclusion: This work reported the characterization of a new triterpenoid (1) and four known constituents (2-5). Compound 1 possessed a moderate activity toward B. cereus.